to evaluate the clinical efficacy and safety of recombinant human interferon ω spray in treatment of viral upper respiratory tract infection in children

Conditions: Viral Upper Respiratory Tract Infection

Summary: to evaluate the clinical efficacy and safety of recombinant human interferon ω spray in treatment of viral upper respiratory tract infection in children aged by 3-12 years, and to explore the appropriate usage and dosage of the drug in treatment of upper respiratory tract infection caused by viruses.

this study is a prospective, randomized, double-blind, double-simulated, placebo parallel-controlled, multi-center clinical study. children who met the inclusion criteria of viral upper respiratory tract infection in eligible children aged by 3-12 years will be enrolled. the study contained 3 treatment groups. xiao'er chaigui tuire keli and xiao'er feire kechuan keli were used as symptomatic treatment drugs in each group, and the two test groups additionally added to different doses of recombinant human interferon ω spray, placebo was added to the placebo group. this study is a prospective, randomized, double-blind, double-simulated, placebo parallel-controlled, multi-center clinical study. children who met the inclusion criteria of viral upper respiratory tract infection in eligible children aged by 3-12 years will be enrolled. the study contained 3 treatment groups. xiao'er chaigui tuire keli and xiao'er feire kechuan keli were used as symptomatic treatment drugs in each group, and the two test groups additionally added to different doses of recombinant human interferon ω spray, placebo was added to the placebo group. in each group, each bottle of drug was sprayed 1 time, sprayed into the child's pharynx, 2 times/dayand should not eat or drink for 20 minutes after using the medicine, xiao'er chaigui tuire keli and xiao'er feire kechuan keli should be taken orally according to the doctor's instructions. the treatment period is 7 days. all subjects returned to the study site for evaluating the primary efficacy measures, secondary efficacy measures and safety measures on treatment day 7±1. telephone follow-up was performed on treatment day 14±2.

Eligibility criteria:
inclusion criteria: * 3 years old ≤ age ≤ 12 years old, gender unlimited； * routine blood test of white cells \< upper limit of normal value, c reactive protein \< upper limit of normal value. meeting the description of the diagnostic criteria for viral upper respiratory tract infection in zhufutang practical pediatrics； * body temperature ≥ 38 ℃（axillary temperature）； * the guardian should give informed consent and sign the informed consent form (if the child is ≥ 10 years old, the child should also give informed consent and sign the informed consent form). exclusion criteria: * diagnosed as bacterial upper respiratory tract infection. * patients with onset time more than 72 hours. * with severe cardiac, hepatic and renal insufficiency（alt and ast are 1.5 times above the upper limit of normal value）, abnormal renal function（scr abnormality） . * treated with antiviral drugs orally within two weeks or for external use within one week before inclusion. * participated in other clinical trials and took the study medication within one month before inclusion. * people with low immune function, systemic failure or long-term use of glucocorticoids and immunosuppressants. * those who suffer from nervous and mental diseases and cannot cooperate well. * allergy constitution（allergic to more than two kinds of drugs or food）or known allergy to interferon and its matrix. * because of other diseases that affect the efficacy observer of this study. * other conditions considered by the investigator as not appropriate to participate in the study.

Keywords: viral upper respiratory tract infection recombinant human interferon ω safety efficacy 3-12 years